AstraZeneca Seeks Edge Over Rivals in Severe Asthma Treatment

By Ben Hirschler LONDON – AstraZeneca hopes to convince doctors its experimental injection for severe asthma has an edge over two approved rivals after clinical trials data on Monday showed it worked well when given just once every two months. The drugmaker has previously flagged benralizumab, which is likely to reach the market next year,

[ Read More ]